You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Ge Healthcare Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Ge Healthcare
International Patents:80
US Patents:4
Tradenames:58
Ingredients:39
NDAs:50
Drug Master File Entries: 5

Drugs and US Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare AMIPAQUE metrizamide INJECTABLE;INJECTION 017982-004 Sep 12, 1983 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Ge Healthcare MYOVIEW 30ML technetium tc-99m tetrofosmin kit INJECTABLE;INJECTION 020372-002 Jul 7, 2005 RX Yes Yes 9,549,999 ⤷  Try a Trial Y ⤷  Try a Trial
Ge Healthcare HYPAQUE diatrizoate meglumine INJECTABLE;INJECTION 016403-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Ge Healthcare HYPAQUE SODIUM 20% diatrizoate sodium SOLUTION;URETERAL 009561-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-002 Dec 26, 1985 4,250,113 ⤷  Try a Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-002 Sep 5, 2007 5,560,903 ⤷  Try a Trial
Ge Healthcare OPTISON albumin human INJECTABLE;INJECTION 020899-001 Dec 31, 1997 6,723,303 ⤷  Try a Trial
Ge Healthcare OMNIPAQUE 300 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-003 Dec 26, 1985 4,021,481 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Ge Healthcare Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0268956 SPC/GB98/040 United Kingdom ⤷  Try a Trial PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
1499331 13C0055 France ⤷  Try a Trial PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
2203431 15C0013 France ⤷  Try a Trial PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
2957286 300962 Netherlands ⤷  Try a Trial PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170721
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.